Innoviva Debt to Equity Ratio 2012-2026 | INVA
Current and historical debt to equity ratio values for Innoviva (INVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Innoviva debt/equity for the three months ending March 31, 2026 was 0.22.
| Innoviva Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.50B | $1.34B | 0.37 |
| 2025-12-31 | $0.46B | $1.17B | 0.39 |
| 2025-09-30 | $0.42B | $1.01B | 0.42 |
| 2025-06-30 | $0.62B | $0.72B | 0.87 |
| 2025-03-31 | $0.61B | $0.65B | 0.94 |
| 2024-12-31 | $0.61B | $0.69B | 0.88 |
| 2024-09-30 | $0.56B | $0.67B | 0.84 |
| 2024-06-30 | $0.56B | $0.67B | 0.84 |
| 2024-03-31 | $0.56B | $0.70B | 0.80 |
| 2023-12-31 | $0.57B | $0.68B | 0.84 |
| 2023-09-30 | $0.56B | $0.63B | 0.89 |
| 2023-06-30 | $0.56B | $0.56B | 1.02 |
| 2023-03-31 | $0.57B | $0.56B | 1.01 |
| 2022-12-31 | $0.67B | $0.57B | 1.18 |
| 2022-09-30 | $0.69B | $0.64B | 1.07 |
| 2022-06-30 | $0.57B | $0.57B | 1.01 |
| 2022-03-31 | $0.56B | $0.55B | 1.01 |
| 2021-12-31 | $0.40B | $0.53B | 0.76 |
| 2021-09-30 | $0.40B | $0.49B | 0.80 |
| 2021-06-30 | $0.40B | $0.39B | 1.00 |
| 2021-03-31 | $0.39B | $0.70B | 0.56 |
| 2020-12-31 | $0.39B | $0.61B | 0.64 |
| 2020-09-30 | $0.39B | $0.54B | 0.72 |
| 2020-06-30 | $0.39B | $0.49B | 0.79 |
| 2020-03-31 | $0.38B | $0.41B | 0.94 |
| 2019-12-31 | $0.38B | $0.34B | 1.12 |
| 2019-09-30 | $0.39B | $0.28B | 1.38 |
| 2019-06-30 | $0.40B | $0.25B | 1.60 |
| 2019-03-31 | $0.39B | $0.20B | 1.95 |
| 2018-12-31 | $0.39B | $0.16B | 2.45 |
| 2018-09-30 | $0.39B | $-0.11B | -3.57 |
| 2018-06-30 | $0.49B | $-0.16B | -3.18 |
| 2018-03-31 | $0.49B | $-0.21B | -2.30 |
| 2017-12-31 | $0.61B | $-0.24B | -2.51 |
| 2017-09-30 | $0.61B | $-0.22B | -2.75 |
| 2017-06-30 | $0.67B | $-0.30B | -2.25 |
| 2017-03-31 | $0.73B | $-0.33B | -2.17 |
| 2016-12-31 | $0.73B | $-0.35B | -2.07 |
| 2016-09-30 | $0.74B | $-0.37B | -2.01 |
| 2016-06-30 | $0.74B | $-0.36B | -2.04 |
| 2016-03-31 | $0.75B | $-0.36B | -2.07 |
| 2015-12-31 | $0.75B | $-0.34B | -2.19 |
| 2015-09-30 | $0.76B | $-0.32B | -2.36 |
| 2015-06-30 | $0.76B | $-0.29B | -2.57 |
| 2015-03-31 | $0.75B | $-0.26B | -2.88 |
| 2014-12-31 | $0.75B | $-0.22B | -3.34 |
| 2014-09-30 | $0.75B | $-0.19B | -3.87 |
| 2014-06-30 | $0.79B | $-0.19B | -4.23 |
| 2014-03-31 | $0.34B | $0.26B | 1.30 |
| 2013-12-31 | $0.38B | $0.30B | 1.28 |
| 2013-09-30 | $0.34B | $0.33B | 1.02 |
| 2013-06-30 | $0.51B | $0.09B | 5.94 |
| 2013-03-31 | $0.50B | $0.09B | 5.46 |
| 2012-12-31 | $0.21B | $0.16B | 1.38 |
| 2012-09-30 | $0.21B | $0.17B | 1.22 |
| 2012-06-30 | $0.21B | $0.19B | 1.11 |
| 2012-03-31 | $0.21B | $0.01B | 34.51 |
| 2011-12-31 | $0.35B | $-0.09B | -3.97 |
| 2011-09-30 | $0.34B | $-0.06B | -5.79 |
| 2011-06-30 | $0.34B | $-0.04B | -9.09 |
| 2011-03-31 | $0.34B | $-0.03B | -12.33 |
| 2010-12-31 | $0.35B | $-0.02B | -15.77 |
| 2010-09-30 | $0.35B | $-0.14B | -2.51 |
| 2010-06-30 | $0.36B | $-0.13B | -2.85 |
| 2010-03-31 | $0.36B | $-0.11B | -3.21 |
| 2009-12-31 | $0.37B | $-0.19B | -1.96 |
| 2009-09-30 | $0.36B | $-0.18B | -2.05 |
| 2009-06-30 | $0.37B | $-0.16B | -2.29 |
| 2009-03-31 | $0.36B | $-0.14B | -2.49 |
| 2008-12-31 | $0.37B | $-0.14B | -2.75 |
| 2008-09-30 | $0.38B | $-0.13B | -3.04 |
| 2008-06-30 | $0.39B | $-0.11B | -3.52 |
| 2008-03-31 | $0.39B | $-0.09B | -4.31 |
| 2007-12-31 | $0.23B | $-0.07B | -3.45 |
| 2007-09-30 | $0.24B | $-0.04B | -5.86 |
| 2007-06-30 | $0.22B | $-0.02B | -14.17 |
| 2007-03-31 | $0.23B | $0.02B | 11.17 |
| 2006-12-31 | $0.20B | $0.06B | 3.15 |
| 2006-09-30 | $0.20B | $0.09B | 2.11 |
| 2006-06-30 | $0.19B | $0.13B | 1.54 |
| 2006-03-31 | $0.17B | $0.16B | 1.08 |
| 2005-12-31 | $0.17B | $0.06B | 2.77 |
| 2005-09-30 | $0.10B | $0.10B | 1.01 |
| 2005-06-30 | $0.10B | $0.13B | 0.75 |
| 2005-03-31 | $0.10B | $0.16B | 0.61 |
| 2004-12-31 | $0.10B | $0.19B | 0.50 |
| 2004-09-30 | $0.10B | $0.11B | 0.90 |
| 2004-06-30 | $0.00B | 0.00 | |
| 2004-03-31 | $0.00B | 0.00 | |
| 2003-09-30 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |